

10/5495 02

JC05 Rec'd PCT/PTO 14 SEP 2005

DOCKET NO.: 277165US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Youcef FEZOU, et al.

SERIAL NO.: NEW U.S. PCT APPLICATION

FILED: HERewith

INTERNATIONAL APPLICATION NO.: PCT/EP04/50320

INTERNATIONAL FILING DATE: March 17, 2004

FOR: AMYLIN AGGREGATION INHIBITORS AND USE THEREOF

REQUEST FOR PRIORITY UNDER 35 U.S.C. 119
AND THE INTERNATIONAL CONVENTION

Commissioner for Patents
Alexandria, Virginia 22313

Sir:

In the matter of the above-identified application for patent, notice is hereby given that the applicant claims as priority:

COUNTRY
EPC

APPLICATION NO
03100683.6

DAY/MONTH/YEAR
18 March 2003

Certified copies of the corresponding Convention application(s) were submitted to the International Bureau in PCT Application No. PCT/EP04/50320. Receipt of the certified copy(s) by the International Bureau in a timely manner under PCT Rule 17.1(a) has been acknowledged as evidenced by the attached PCT/IB/304.

Respectfully submitted,
OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Richard L. Treanor
Attorney of Record
Registration No. 36,379

Customer Number

22850

Fax No. (703) 413-2220
(OSMMN 08/03)

Surinder Sachar
Registration No. 34,423



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

PCT/EP200 4 / 0 5 0 3 2 0

17.03.2004

REC'D 07 JUN 2004	
WIPO	PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03100683.6

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1 (a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Anmeldung Nr:
Application no.: 03100683.6
Demande no:

Anmeldetag:
Date of filing: 18.03.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Applied Research Systems ARS Holding N.V.
Pietermaai 15
Curacao
ANTILLES NEERLANDAISES

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se referer à la description.)

Amylin aggregation inhibitors and use thereof

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07K7/06
A61K38/22
A61P5/48

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT SE SI SK TR LI RO

Amylin aggregation inhibitors and use thereof.

Field of the invention


The invention relates to the field of β -sheet breaking peptides, particularly to their use
5 in the treatment of Type II diabetes.

Background of the invention


Type-II diabetes is a heterogeneous and multi-factorial disease characterized by beta-cell failure, insulin resistance, and the presence of amyloid deposits in the pancreatic
10 islets of about 90% of patients (*Anguinao et al. 2002*). The major component of these deposits is a 37 amino acid peptide called islet amyloid polypeptide (IAPP) or amylin (*Cooper et al., 1987*). Amylin is a normal secretory product of the pancreatic beta cells, stored in the same granules as insulin and is co-released with insulin during the process of exocytosis. The normal function of soluble amylin is to control glucose homeostasis,
15 possibly as an insulin counter-regulatory hormone (*Rink et al., 1993*). However, under certain conditions, the increase in amylin secretion leads to formation amyloid fibrils that deposit in the pancreas of Type II diabetes patients. The formation of amyloid deposits is strongly associated with continuous decline of beta cell function and the progression of the disease (*Höppener et al., 2000*). A strong evidence for the
20 importance of amyloid in the pathogenesis of diabetes Type II comes from genetic studies showing that mutations in amylin gene result in early onset hereditary disease, specially when accompanied with obesity.

IAPP fibril formation has also been found in patients with Type I diabetes post-transplantation. Therefore, the amyloidogenic protein IAPP, that has been shown to
25 induce β -islet cell toxicity *in vitro*, may contribute to the loss of β -islet cells (Langherans) and organ dysfunction by the formation of fibrils in the pancreas of Type I or Type II diabetic patients.

- Amylin fibril formation involves the conversion of an irregularly structured conformer (random coil, soluble form) into a highly stable, β -sheet-rich fibrillar aggregates. As in the case of amyloid beta in Alzheimer's disease, the random-coil to β -sheet conversion is believed to be one of the earliest events of amylin fibril formation. Therefore,
- 5 diabetes Type II is included in the group of diseases in which protein misfolding and aggregation is a hallmark event in the disease (*Soto et al., 2000; Carrell et al., 1997; Dobson, 1999*). The central region of amylin sequence, residues 20-29, has been found to be very important for fibril formation (*Glenner et al., 1988; Westermark et al., 1990*) and thus might be the sequence where the conversion to β -sheet occurs.
- 10 A human amylin analogue of 37 amino acid, Pramlintide acetate (Symlin®) is being developed by Amylin Pharmaceuticals Inc. as an adjunct with insulin for the potential prevention of complications of Type I diabetes and as a single agent for Type II diabetes.
- 15 One approach to the treatment and prevention of disorders associated with protein misfolding and aggregation has been to develop short peptides having some sequence homology to the natural protein sequence believed to be involved in amyloid formation, but also having one or more amino acids that disfavour or destabilise the formation of β -pleated sheet conformations. The peptides prevent the aggregation of β -amyloid, and
- 20 thereby prevent its cytotoxic effects. This approach has been suggested in Alzheimer's disease and in prion-related disorders (WO 96/39834, New York University and WO 01/34631, Axonyx Inc.) and has lead to the β -sheet breaking peptides shown below, amongst others:



WO 96/39834 (New York University)



WO 01/34631 (Axonyx, Inc.)

The amino acid proline has been used frequently to destabilize the formation of β -sheet structure, because its physicochemical and structural properties determine that this residue is rarely found inside β -sheet structures. Interestingly, a comparison of the amylin sequence from different species shows that species where a diabetic condition has been reported (human and cats) have a lower number of prolines in the 20-29 region of amylin compared with rodents where amyloid deposition and diabetes has not been shown (Fig. 1) (*Moriarty et al. 1999*). These findings are consistent with the role of amylin aggregation in the pathogenesis of diabetes Type II and further support the concept of β -sheet breaker peptides useful as inhibitors of amyloid formation.

Summary of the invention

It is an object of the invention to provide substances which are suitable for the treatment of and/or prevention of and/or delaying the progression of diabetes, notably Type II diabetes.

It is also an object of the invention to provide substances which are suitable for reducing or inhibiting amylin aggregation.

It is notably an object of the invention to provide β -sheet breaking peptides which are suitable for reducing or inhibiting amyloid formation by amylin.

In a first aspect, the invention provides peptides having an amino acid sequence of Formula I (SEQ ID NO. 1):

$X_1FGAPX_2X_3$ in which

X_1 , is selected from Aspartic acid and derivative thereof;

X_2 is Leucine or when X_3 is absent, X_2 is selected from Leucine and derivative thereof;

X_3 can be absent or is selected from Aspartic acid and derivatives thereof;

wherein F represents Phenylalanine, G represents Glycine, A represents Alanine and P represents Proline.

In a second aspect, the present invention provides compounds of formula I for use as a medicament.

In a third aspect, the invention provides a pharmaceutical composition comprising a compound of formula I, together with a pharmaceutically acceptable excipient or carrier.

5

In a fourth aspect, the invention provides a use of formula I for the preparation of a medicament for the treatment or prevention of a diabetic conditions selected from post-transplantation Type I diabetes and Type II diabetes.

- 10 In a fifth aspect, the invention provides a method for treating a disease associated with abnormal folding of the islet amyloid polypeptide.

In a sixth aspect, the invention provides a method for treating a patient suffering from diabetes, notably Type II diabetes.

15

Detailed description of the invention

The following paragraphs provide definitions of various chemical moieties and terms, and are intended to apply uniformly throughout the specification and claims unless an otherwise expressly set out definition provides a different definition.

20

The term "peptide" is ordinarily applied to a polypeptidic chain containing from 3 to 30 or more contiguous amino acids, usually from 3 to 20 contiguous amino acids. Such peptides can be generated by methods known to those skilled in the art, including partial proteolytic cleavage of a larger protein, chemical synthesis, or genetic engineering.

25

The expression "derivative or analogue" means any compound the chemical structure of which contains modifications with respect to the parent peptide, but which maintains at least 50%, more preferably at least 75%, most preferably at least 90% of the biological activity of a compound of formula I.

30

The term "derivatives" as herein used refers to derivatives which can be prepared from the functional groups present on the lateral chains of the amino acid moieties or on the

N-/ or C-terminal groups according to known methods. Such derivatives include for example esters or aliphatic amides of the carboxyl-groups and N-acyl derivatives of free amino groups or O-acyl derivatives of free hydroxyl-groups and are formed with acyl-groups as for example alcanoyl- or aroyl-groups.

5

The term "salts" herein refers to both salts of carboxyl groups and to acid addition salts of amino groups of the peptides, polypeptides, or analogs thereof, of the present invention. Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases as those formed, for example, with amines, such as triethanolamine, arginine or lysine, piperidine, procaine and the like. Acid addition salts include, for example, salts with mineral acids such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids such as, for example, acetic acid or oxalic acid. Any of such salts should have substantially similar activity to the peptides and polypeptides of the invention or their analogs.

15

The polypeptides and the peptides of the present invention can be in other alternative forms which can be preferred according to the desired method of use and/or production, for example as active fractions, precursors, salts, derivatives, conjugates or complexes.

20

The compounds of the invention may be prepared by any well-known procedure in the art, including chemical synthesis technologies.

25

Examples of chemical synthesis technologies are solid phase synthesis and liquid phase synthesis. As a solid phase synthesis, for example, the amino acid corresponding to the C-terminus of the peptide to be synthesized is bound to a support which is insoluble in organic solvents, and by alternate repetition of reactions, one wherein amino acids with their amino groups and side chain functional groups protected with appropriate protective groups are condensed one by one in order from the C-terminus to the N-terminus, and one where the amino acids bound to the resin or the protective group of the amino groups of the peptides are released, the peptide chain is thus

30


extended in this manner. Solid phase synthesis methods are largely classified by the tBoc method and the Fmoc method, depending on the type of protective group used. Typically used protective groups include tBoc (t-butoxycarbonyl), Cl-Z (2-chlorobenzoyloxycarbonyl), Br-Z (2-bromobenzoyloxycarbonyl), Bzl (benzyl), Fmoc (9-fluorenylmethoxycarbonyl), Mbh (4,4'-dimethoxydibenzhydryl), Mtr (4-methoxy-2,3,6-trimethylbenzenesulphonyl), Trt (trityl), Tos (tosyl), Z (benzyloxycarbonyl) and Cl₂-Bzl (2,6-dichlorobenzyl) for the amino groups; NO₂ (nitro) and Pmc (2,2,5,7,8-pentamethylchromane-6-sulphonyl) for the guanidino groups; and tBu (t-butyl) for the hydroxyl groups). After synthesis of the desired peptide, it is subjected to the de-protection reaction and cut out from the solid support. Such peptide cutting reaction may be carried with hydrogen fluoride or tri-fluoromethane sulfonic acid for the Boc method, and with TFA for the Fmoc method.

The present invention provides compounds capable of controlling IAPP aggregation and fibril formation

The activity of the compound of the invention in inhibiting the amylin fibrils can be detected using, for example, an *in vitro* assay, such as that described by *Khunk et al., 1999 and Fezoui et al., 1999*, which measures the ability of compounds of the invention to prevent the aggregation of the islet amyloid polypeptide (IAPP). Results are reported in the Examples.

Amylin fibrils are cytotoxic, inducing cell death by apoptosis (*Lorenzo et al., 1994*). Compounds of the invention can be tested for their ability to prevent cytotoxicity of amylin fibrils. Results are reported in the Examples.

In an embodiment, peptides of the invention are of following Formula II:




5

Formula II

wherein R^1 is selected from H, optionally substituted C_2-C_6 acyl and optionally substituted C_1-C_6 alkyl, preferably H and acyl; R^2 is selected from OH and NR^3R^4 , wherein R^3 and R^4 are independently selected from H and optionally substituted C_1-C_6 alkyl, preferably OH and NH_2 ; R^5 , R^6 , R^7 , R^8 and R^9 are independently selected from H and C_1-C_6 alkyl.

10

In another embodiment, peptides of the invention are of following Formula III:



15

Formula III

wherein R^1 is selected from H, optionally substituted C_2-C_6 acyl and optionally substituted C_1-C_6 alkyl, preferably H and acyl and R^2 is selected from OH and NR^3R^4 , wherein R^3 and R^4 are independently selected from H and optionally substituted C_1-C_6 alkyl, preferably OH or NH_2 ; R^5 , R^6 , R^7 and R^8 are independently selected from H and C_1-C_6 alkyl.

20

In another embodiment of the invention, peptides of formula I are selected from the group consisting of SEQ ID NO. 2, SEQ ID NO. 3 and. SEQ ID NO. 4.

5 In another embodiment of the invention, peptides of formula I can be used for the preparation of a medicament for the treatment or prevention of IAPP related disorders such as diabetes Type I or Type II, e.g. to prevent or delay the aggregation of amylin associated with the onset and/or progression of Type II diabetes or for the treatment of islet cells, e.g. cultured pancreatic islet cells *in vitro* prior to their transplantation, for the treatment of Type I diabetes patients, e.g., post-transplantation, to prevent or inhibit
10 fibril formation in the transplanted cells.

Still another embodiment of the present invention, is a method for treating or preventing an IAPP related amyloidosis, such as a diabetic disorder, preferably Type II diabetes or post-transplantation Type I diabetes.

15

A further embodiment of the invention is a method for treating or preventing IAPP disorders wherein the method comprises administering an effective dose of the above-mentioned peptides and derivatives thereof to a subject in the need thereof, wherein the subject can be human or animal, preferably human.

20

A further embodiment of the invention comprises the administration of at least a compound of the invention in a regimen coordinated with insulin or with glucose sensitizers, e.g. in a treatment for diabetes for simultaneous, sequential or separate use.

25 Pharmaceutical compositions comprising at least one peptide of the invention include all compositions wherein the peptide(s) are contained in an amount effective to achieve the intended purpose. In addition, the pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used
30 pharmaceutically. Suitable pharmaceutically acceptable vehicles are well known in the art and are described for example in *Gennaro et al, 2000*, a standard reference text in this field. Pharmaceutically acceptable vehicles can be routinely selected in accordance

with the mode of administration and the solubility and stability of the peptides. For example, formulations for intravenous administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives. The use of biomaterials and other polymers for drug delivery, as well the different techniques and models to validate a specific mode of administration, are disclosed in literature (*Luo et al., 2001; Cleland et al., 2001*).

The above-mentioned peptides and derivatives of the present invention may be administered by any means that achieves the intended purpose. For example, administration may be by a number of different routes including, but not limited to subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intra-cerebral, intrathecal, intranasal, oral, rectal, transdermal, intranasal or buccal. Preferably the compounds of the invention are administered by subcutaneous, intramuscular or intravenous injection or infusion.

Parenteral administration can be by bolus injection or by gradual perfusion over time. A typical regimen for preventing, suppressing, or treating amylin misfolding related disorders, comprises either (1) administration of an effective amount in one or two doses of a high concentration of inhibitory peptides in the range of 0.5 to 10 mg of peptide, more preferably 0.5 to 5 mg of peptide, or (2) administration of an effective amount of the peptide in multiple doses of lower concentrations of inhibitor peptides in the range of 10-1000 μ g, more preferably 50-500 μ g over a period of time up to and including several months to several years. It is understood that the dosage administered will be dependent upon the age, sex, health, and weight of the recipient, concurrent treatment, if any, frequency of treatment, and the nature of the effect desired. The total dose required for each treatment may be administered by multiple doses or in a single dose.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions, which may contain auxiliary agents or excipients which are known in the art. Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble

form, for example, water-soluble salts. In addition, suspension of the active compound as appropriate oily injections suspensions may be administered.

Depending on the intended route of delivery, the compounds may be formulated as injectable or oral compositions. The compositions for oral administration can take the form of bulk liquid solutions or suspensions, or bulk powders. More commonly, however, the compositions are presented in unit dosage forms to facilitate accurate dosing. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a pre-determined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Typical unit dosage forms include pre-filled, pre-measured ampoules or syringes of the liquid compositions or pills, tablets, capsules or the like in the case of solid compositions. In such compositions, the compound of the invention is usually a minor component (from about 0.1 to about 50% by weight or preferably from about 1 to about 40% by weight) with the remainder being various vehicles or carriers and processing aids helpful for forming the desired dosing form.

Liquid forms suitable for oral administration may include a suitable aqueous or non-aqueous vehicle with buffers, suspending and dispensing agents, colorants, flavours and the like. Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatine; an excipient such as starch or lactose; a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavouring agent such as peppermint, methyl salicylate, or orange flavouring.

Injectable compositions are typically based upon injectable sterile saline or phosphate-buffered saline or other injectable carriers known in the art.

The above-described components for orally administered or injectable compositions are merely representative. Further materials as well as processing techniques and the like are known to the skilled practitioner (*Gennaro et al., 2000*).

- 5 The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials is also known to the skilled practitioner (*Karsa et al., 1993; Yacobi et al., 1998*).
- 10 By "effective amount", is meant an amount sufficient to achieve a concentration of peptide(s) which is capable of slowing down or inhibiting the formation of amylin deposits, or of dissolving preformed deposits. Such concentrations can be routinely determined by those of skill in the art. The amount of the compound actually administered will typically be determined by a physician, in the light of the relevant
- 15 circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like. It will also be appreciated by those of skill in the art that the dosage may be dependent on the stability of the administered peptide. A less stable peptide may require administration in multiple
- 20 doses.

The expression "Pharmaceutically acceptable" is meant to encompass any carrier, which does not interfere with the effectiveness of the biological activity of the active ingredient and that is not toxic to the host to which is administered. For example, for

25 parenteral administration, the above active ingredients may be formulated in unit dosage form for injection in vehicles such as saline, dextrose solution, serum albumin and Ringer's solution.

Besides the pharmaceutically acceptable carrier, the compositions of the invention can

30 also comprise minor amounts of additives, such as stabilizers, excipients, buffers and preservatives.

The present invention has been described with reference to the specific embodiments, but the content of the description comprises all modifications and substitutions, which can be brought by a person skilled in the art without extending beyond the meaning and purpose of the claims.

5

The invention will now be described by means of the following Examples, which should not be construed as in any way limiting the present invention. The Examples will refer to the Figures specified here below.

10

Brief description of the drawings:

Fig. 1 compares sequences of human, cat, mouse, rat and hamster amylin. The amyloidogenic domain spanning residues 20-29 is shown by arrows and the sequence used as a template to generate β -sheet breaker peptides is highlighted in bold.

Fig. 2 shows the effect of peptide of Example SEQ ID NO. 2 on amyloid cytotoxicity. Soluble amylin (100 μ M), soluble amylin (100 μ M) + peptide of SEQ ID NO. 2 (800 μ M), and peptide of SEQ ID NO. 2 (800 μ M) were preincubated at 37°C in Tris buffer pH 7.4 for 24h then diluted in 50 μ l of culture medium before addition to Rin-m5F cells, to yield final concentrations of 2 μ M (amylin) and 16 μ M (peptide of SEQ ID NO. 2). Data are expressed as average MTT reduction \pm SD (n=5) relative to cells treated with medium alone, which was made to equal 100%.

Fig. 3 shows the linear relationship between IC₅₀ of peptide of SEQ ID NO. 2 in preventing cytotoxicity in vitro and amylin concentration. Aliquots of 2.5, 10, 50 and 100 μ M of amylin were incubated during 24h at 37°C with different concentrations of peptide of SEQ ID NO. 2. Thereafter the samples were diluted in cell culture medium and cytotoxicity assay performed as described in Example 2.

30

Abbreviations

5 μ l (microliters), μ M (micromolar), mg (milligrammes), min (minutes), ml (milliliters),
 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), nm
 (nanometers), PBS (Phosphate Buffered Sulfate), pM (picomolar), RT (room
 temperature), SDS (Sodium Dodecyl Sulfate), TFA (trifluoroacetic acid).

EXAMPLES

The invention will be illustrated by means of the following examples which are not to be construed as limiting the scope of the invention.

10 The following examples illustrate preferred compounds according to formula I, and
 methods for determining their biological activities.

15 Synthetic human amylin (1-37) (TFA salt) and A β ₁₋₄₂ were synthesized in solid phase at
 W.M. Keck Foundation, Yale University. Amylin was not chemically reduced to make
 sure that the cystein bridge between amino acids 2 and 7 was formed. Control peptides,
 and the prion protein fragment 106-126 were purchased from Neosystem. In order to
 increase the solubility of amylin (1-37), HCl salt of amylin was made by dissolving 1
 mg of amylin in 1 ml of 2 mM HCl solution, sonicated for 1 min at RT in an ultrasonic
 water bath, then lyophilized in aliquots of 0.2 mg and kept dry at 4°C until use.

20

Example 1: Synthesis of compounds of the invention

25 Inhibitor peptides were synthesized in solid phase by Neosystem. Peptides were purified
 by HPLC and purity (> 95%) evaluated by peptide sequencing and laser desorption
 mass spectrometry. Stock solution of the peptides were prepared in water/0.1%
 trifluoroacetic acid and stored lyophilized in aliquots at -70°C. Concentration of the
 stock solution was estimated by amino acid analysis.

The chemical derivatization reactions were done during the synthesis by Neosystem using standard procedures.

30

The molecular weights measured by mass spectrometry are listed in Table I below:

Table I:

SEQ ID N°.	MW (g/mol)
2	619
3	660
4	734
10	720
11	705
12	749
13	699
14	790
15	776
16	733
17	618

5 **Example 2: Biological assays**

***In vitro* peptide solubility assay:**

Solubility of peptides of the invention was obtained using a qualitative assay where the peptide was dissolved in Tris buffer, pH 7.4 at 1, 5, or 10 mg/ml, vortexed briefly, and then centrifuged at 16, 000 g for 30 min. The presence of a pellet in the bottom of the tube indicates that the peptide is not soluble at the respective concentration.

The data in Table II below indicate that peptides of the invention are highly soluble:

Table II

SEQ ID N°.	Solubility
10	<200µg/ml
11	<1mg/ml
12	2mg/ml
4	>10mg/ml
3	>10mg/ml

SEQ ID N°.	Solubility
2	>10mg/ml

***In vitro* assays of activity:**

The activity of compounds of the invention in inhibiting the formation of aggregated amylin fibrils can be tested by absorbance changes.

5

Amyloid formation was quantitatively evaluated by measuring the amount of bound Congo red (Cb) to the fibrils using the formula below as reported (*Klunk et al., 1999*):

$$\text{Cb } (\mu\text{M}) = (\text{A}_{541}/47,800) - (\text{A}_{403}/68,300) - (\text{A}_{403}/86,200)$$

wherein A_{541} and A_{403} are the absorbances respectively at 541 and 403 nm.

10

Aliquots of amylin at a concentration of 0.4 mg/ml prepared in 50 mM Tris-HCl, pH 7.4 were incubated at 37°C for 48h in the absence or presence of 1 mg/ml of the peptide of the invention. At the end of the incubation time, 125 μl of 15 μM Congo red in PBS was added to 25 μl of sample, mixed and incubated for 10 min at RT. The absorbance of the resulting solutions was then measured at 403 and 541 nm. The amount of Congo red was calculated using the above formula. The amount of Congo red bound to amylin fibrils in the absence of the inhibitor was set to 100%.

15

The data presented in Table III below indicate that peptides of the invention inhibit amylin aggregates formation:

20

Table III

SEQ ID N°.	% Inhibition of Amylin fibrils
Amylin	0
12	20
13	16
14	8
15	10

SEQ ID N°.	% Inhibition of Amylin fibrils
16	24
4	39
3	47
2	43

Cellular assays of activity:

The mechanism proposed for the implication of amylin misfolding and aggregation in the pathogenesis of Type II diabetes is by inducing islet β -cell death and thus pancreas dysfunction. The ability of compounds of the invention to prevent or reduce the formation of cytotoxic amylin fibrils (*Lorenzo et al., 1994*) was evaluated by measuring the inhibition of amylin induced cytotoxicity in pancreatic β -cells.

Toxicity was measured by comparing the effects of amylin or amylin combined with peptides of the invention, on the reduction of the redox active dye, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) by PC12 cells or Rin-m5F cells (ATCC), a pancreatic beta cell line. Cells were grown in RPMI-1640 media containing 10% foetal bovine serum, and plated onto 96-well plates.

Amylin at 0.2 mg/ml in 50 mM Tris-HCl pH 7.4, in the absence or presence of 1 mg/ml of peptide of the invention, was incubated at 37°C for 48 h, then diluted in 50 μ l of culture media at the appropriate peptide concentration before addition to the Rin-m5F cells. After overnight incubation, 10 μ l of 2.5 mg/ml MTT was added to each well and the incubation continued for a further 3 h. Cells were then solubilized in 200 μ l of 20% (w/v) SDS in 50% (v/v) *N,N*-dimethylformamide, 25 mM HCl, 2% (v/v) glacial acetic acid, pH 4.7, by overnight incubation at 37 °C. Levels of reduced MTT were determined by measuring the difference in absorbance at 595 and 650 nm using a microplate reader.

Cell viability is measured in presence of amylin alone and for a mixture of amylin and peptides of the invention. Cell viability in presence of a mixture of amylin and compound of SEQ ID NO. 2 is presented in Figure 2 in comparison with amylin alone. The percentage of inhibition of cellular toxicity is calculated for the mixtures in comparison to cellular toxicity induced by amylin alone. Percentages of inhibition of cellular toxicity are presented in Table IV below for compounds of the invention:

Table IV

SEQ ID N°.	% Inhibition Amylin fibrils cytotoxicity
Amylin	0
17	19
4	33
3	43
2	40

10

Since the concentration at which the inhibitory effect of peptides of the invention is observed depends on the concentration of amylin used, the concentration of amylin was varied and the inhibitory concentration at 50% of the effect (IC_{50}) of compound of SEQ ID NO. 2 was calculated. For this, aliquots of 2.5, 10, 50 and 100 μ M of amylin were incubated during 24h at 37°C with different concentrations of peptide SEQ ID NO. 2. Thereafter the samples were diluted in cell culture medium and cytotoxicity assay performed.

As shown in Figure 3, the IC_{50} for peptide of SEQ ID NO. 2 has a linear relationship with amylin concentration. IC_{50} were found to be 1.5-2.7-fold higher than amylin concentrations used in the study. Considering that amylin concentration in blood has

20

been shown to be 2-3 pM, we estimate that the peptide concentration in plasma in which a 50% of activity would be reached in vivo is 4-6 pM.

5 Selectivity of the effect of peptides of the invention was assayed in the same assay as presented above.


Selectivity of peptides of the invention towards amylin was tested by measuring the ability of peptides of the invention to inhibit cellular toxicity induced by prion protein fragment (PrP₁₀₆₋₁₂₆) by A β ₁₋₄₂ peptide. Peptides of the invention were not able to
10 inhibit either cellular toxicity of prion, nor A β fibrils.

References

- Anguinao et al. 2002**, *Biochemistry*, 41, 11338-11343;
- Carrell et al. 1997**, *The Lancet*, 350, 134-8;
- 5 **Cleland et al.**, *Curr Opin Biotechnol*, 12: 212-9, 2001;
- Cooper GJ et al. 1987**, *Proc. Natl. Acad. Sci. U.S.A.*, 84:8628-32;
- Dobson 1999**, *Trends Biochem. Sci.* 24, 329-32;
- Fezoui et al. 1999**, *Int. J. Exp. Clin. Invest.* 7, 166-178;
- Gennaro et al. 2000**, of *Remington's Pharmaceutical Sciences*, Part 8, 20th Edition,
- 10 **Marck Publishing Company**, Easton, Pennsylvania;
- Glennner et al. 1988**, *Biochem. Biophys. Res. Commun* 155, 608;
- Höppener JWM et al. 2000**, *N. Engl. J. Med.*, 343, 411-419;
- Karsa et al. 1993**, (Ed), *Encapsulation and Controlled Release*; Stephenson (Editor); Springer Verlag;
- 15 **Klunk et al. 1999**, *Methods Enzymol.*, 309:285-305;
- Lorenzo et al. 1994**, *Nature* 368: 756-760;
- Luo et al. 2001**, *Exp Opin Ther Patents*, 11: 1395-1410;
- Moriarty et al. 1999**, *Biochemistry*, 38, 1811-1818;
- Rink et al. 1993**, *Trends in Pharmacol Sci.* 14, 113-118;
- 20 **Soto et al. 2000**, *FEBS Lett.*, 498, 204-7;
- Westermarck et al. 1990**, *Proc. Natl. Acad. Sci. U.S.A.* 87:5036-40;
- Yacobi et al. 1998**, *Oral Sustained Release Formulations: Design and Evaluation*, Eva Halperin-Walega (Editor), 1st Ed. edition; Pergamon Press;
- WO 96/39834**, New York University;
- 25 **WO 01/34631**, Axonyx Inc.

Claims

1. A peptide having an amino acid sequence of Formula I (SEQ ID NO: 1):
 $X_1FGAPX_2X_3$ in which
 X_1 , is selected from Aspartic acid and derivative thereof;
 X_2 is Leucine or when X_3 is absent, X_2 is selected from Leucine and derivative thereof;
 X_3 can be absent is selected from Aspartic acid and derivative thereof;
 as well as salt and any derivative or analogue thereof.
2. A peptide according to claim 1 wherein X_1 and X_3 are aspartic acid.
3. A peptide according to claim 1 or 2 of formula II below:




Formula II

wherein R^1 is selected from H, C_2-C_6 acyl and C_1-C_6 alkyl; R^2 is selected from OH and NR^3R^4 , wherein R^3 and R^4 are independently selected from H and C_1-C_6 alkyl and R^5, R^6, R^7, R^8 and R^9 are independently selected from H and C_1-C_6 alkyl.

4. A peptide according to claim 3 wherein R^1 is selected from H and acyl and R^2 is selected from OH and NH_2 .
5. A peptide according to any of the preceding claims wherein R^5, R^6, R^7, R^8 and R^9 are H.

6. A peptide according to claim 1 of formula III below:



Formula III

wherein R^1 is selected from H, C_2-C_6 acyl and C_1-C_6 alkyl; R^2 is selected from OH and NR^3R^4 , wherein R^3 and R^4 are independently selected from H and C_1-C_6 alkyl and R^5 , R^6 , R^7 and R^8 are independently selected from H and C_1-C_6 alkyl.

7. A peptide according to claim 3 wherein R^1 is selected from H and acyl and R^2 is selected from OH and NH_2 .

8. A peptide according to any of the preceding claims wherein R^5 , R^6 , R^7 and R^8 are H.

9. A peptide according to any preceding claims selected from the following group:
SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4.

10. A compound according to any of the preceding claims for use as a medicament.

11. Use of a peptide according to claims 1 to 9 for the preparation of a medicament in the treatment or prevention of an amyloidosis disorder related to IAPP.

12. Use according to claim 11 wherein the amyloidosis disorder is a diabetic disorder.

13. Use according to claim 12 wherein the diabetic condition is Type II diabetes.

14. Use according to claim 12 wherein the diabetic condition is post-transplantation Type I diabetes.
- 5 15. A pharmaceutical composition comprising a compound according to claims 1 to 9 as active ingredient and a pharmaceutically acceptable excipient or carrier.
- 10 16. A method of treating or preventing diabetic disorders by administering an effective amount of any of the peptides or compounds of claims 1 to 9 to a subject in the need thereof.
17. A method according to claim 16, in which the subject is human.

Abstract

Short peptides and derivatives or analogs thereof for the treatment or prevention of IAAP related disorders, in particular amyloid deposits associated with Type I or Type II diabetes are herein described. These peptides and/or their derivatives have been designed to inhibit the formation of amylin fibrils which are implicated in the pathogenesis of diabetes Type II as well as to dissolve the fibrillar deposits already formed

SEQUENCE LISTING

<110> APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

<120> Amylin aggregation inhibitors and use thereof.

<130> EP/817

<160> 17

<170> PatentIn version 3.1

<210> 1

<211> 7

<212> PRT

<213> synthetic construct

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> Xaa, if present, can be Aspartic acid or derivative thereof;

<220>

<221> MISC_FEATURE

<222> (6)..(6)

<223> Xaa is Leucine or when Xaa in position 7 is absent, Xaa is Leucine or a derivative thereof

<220>

<221> MISC_FEATURE

<222> (7)..(7)

<223> Xaa can be absent or is selected from Aspartic Acid and a derivtive thereof

<400> 1

Xaa Phe Gly Ala Pro Xaa Xaa
1 5

<210> 2
<211> 6
<212> PRT
<213> synthetic construct

<400> 2

Asp Phe Gly Ala Pro Leu
1 5

<210> 3
<211> 6
<212> PRT
<213> synthetic construct

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa is acetylated aspartic acid

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa is amidated Leucine

<400> 3

Xaa Phe Gly Ala Pro Xaa
1 5

<210> 4
 <211> 7
 <212> PRT
 <213> synthetic construct

<400> 4

Asp Phe Gly Ala Pro Leu Asp
 1 5

<210> 5
 <211> 37
 <212> PRT
 <213> human

<400> 5

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15

Val His Ser Ser Asn Asn Phe Gly Ala Ile Leu Ser Ser Thr Asn Val
 20 25 30

Gly Ser Asn Thr Tyr
 35

<210> 6
 <211> 37
 <212> PRT
 <213> Cat

<400> 6

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15

Ile Arg Ser Ser Asn Asn Leu Gly Ala Ile Leu Ser Pro Thr Asn Val
 20 25 30

Gly Ser Asn Thr Tyr
 35

<210> 7
 <211> 37
 <212> PRT
 <213> Hamster

<400> 7

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
 1 5 10 15

Val His Ser Ser Asn Asn Leu Gly Pro Val Leu Ser Pro Thr Asn Val
 20 25 30

Gly Ser Asn Thr Tyr
 35

<210> 8
 <211> 37
 <212> PRT
 <213> Rat

<400> 8

5

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 9
<211> 37
<212> PRT
<213> Mouse

<400> 9

Lys Cys Asn Thr Ala Thr Cys Ala Thr Gln Arg Leu Ala Asn Phe Leu
1 5 10 15

Val Arg Ser Ser Asn Asn Leu Gly Pro Val Leu Pro Pro Thr Asn Val
20 25 30

Gly Ser Asn Thr Tyr
35

<210> 10
<211> 7
<212> PRT
<213> human

<400> 10

Asn Phe Gly Ala Ile Leu Ser
1 5

<210> 11
<211> 7
<212> PRT
<213> synthetic constuct

<400> 11

Asn Phe Gly Ala Pro Leu Ser
1 5

<210> 12
<211> 7
<212> PRT
<213> synthetic construct

<400> 12

Asp Phe Gly Ala Ile Leu Asp
1 5

<210> 13
<211> 7
<212> PRT
<213> synthetic construt

<400> 13

Asp Pro Gly Ala Ile Leu Asp
1 5

<210> 14

<211> 7
<212> PRT
<213> synthetic construct

<400> 14

Asp Phe Pro Ala Ile Leu Asp
1 5

<210> 15
<211> 7
<212> PRT
<213> synthetic construct

<400> 15

Asp Phe Gly Pro Ile Leu Asp
1 5

<210> 16
<211> 7
<212> PRT
<213> synthetic construct

<400> 16

Asp Phe Gly Ala Ile Pro Asp
1 5

<210> 17
<211> 6
<212> PRT
<213> synthetic construct

<400> 17

Phe Gly Ala Pro Leu Asp


1

5


Figure 1



2/3
Figure 2



3/3
Figure 3



Ms CT/EP004/050320



This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**